MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine agonists"

  • MDS Virtual Congress 2021

    Using a Dopamine Genetic Risk Score to Predict Impulse Control Behaviours for Parkinson’s Disease Patients

    A. Hall, N. Jenkinson, H. Macdonald (Birmingham, United Kingdom)

    Objective: The current study aimed to utilise a dopamine genetic risk score and objective laboratory-based behavioural measures of impulse control to identify Parkinson’s patients most…
  • MDS Virtual Congress 2021

    Distinct oscillatory fingerprints in dyskinesias mediated by D1 versus D2 receptors

    K. Skovgård, P. Halje, SA. Barrientos, P. Petersson, MA. Cenci (Lund, Sweden)

    Objective: To characterize the patterns of cortico-basal ganglia oscillations induced by D1 or D2 receptor agonists in a rat model of L-DOPA-induced dyskinesia. Background: In…
  • MDS Virtual Congress 2021

    Deterioration in oral health status potentially associated with apomorphine pump initiation: a case report

    M. Auffret, V. Mathaut-Malefant, V. Denys, M. Tra, E. Boyer, V. Meuric, M. Bonnaure-Mallet, M. Vérin (Rennes, France)

    Objective: To describe the case of a patient with Parkinson’s disease (PD) who suffered from a rapid deterioration of his oral health status following treatment…
  • MDS Virtual Congress 2020

    Parkinson’s disease and osteocalcin pilot study: Is there a protective role of bone in neurodegeneration?

    A.S Nordvig, R.N Alcalay, J.M Berger, K. Marder, G. Karsenty, A. Wang (New York, NY, USA)

    Objective: To characterize the relationship between the bone-derived hormone osteocalcin (OCN) and Parkinson’s disease (PD) in humans, and explore sex and treatment differences. Background: The…
  • MDS Virtual Congress 2020

    Claims Data Analysis of Parkinson’s Disease Medication Utilization

    M. Frazer, C. Blauer-Peterson, R. Sasane, S. Arcona, Y. Fang, R. Halpern (Eden Prairie, MN, USA)

    Objective: Characterize prominent medication utilization patterns among patients with Parkinson’s disease (PD). Background: Multiple classes of medications, as monotherapy or polytherapy, are prescribed to treat…
  • MDS Virtual Congress 2020

    Epidemiology of Impulse Control Disorders and Association with Dopamine Agonist Exposure in the United States Military

    A. Garrett, S. Bazaco, S. Clausen, A. Oetting, S. Stahlman (San Diego, CA, USA)

    Objective: Evaluate the epidemiology of impulse control disorders in the US Military and their association with dopamine agonist exposure. Background: Impulse control disorders (ICDs) are…
  • MDS Virtual Congress 2020

    Frequency and risk factors of dopamine agonist-induced peripheral edema in patients with Parkinson’s disease

    S. Bostan, N. Durmaz Çelik, S. Özkan (Eskisehir, Turkey)

    Objective: To determine the frequency and risk factors of peripheral edema (PE) development and whether discontinuation of the drug is enough for treatment. To determine…
  • MDS Virtual Congress 2020

    Accounting for unmeasured confounders in treatment response: a comparison of levodopa versus non-levodopa dopaminergic drugs

    M. Javidnia, W. Artman, J. Jones, A. Ertefaie, C. Venuto (Rochester, NY, USA)

    Objective: To compare short-term levodopa and non-levodopa dopaminergic treatment response in people with Parkinson’s disease (PD) using instrumental variable analysis and linear regression. Background: Treatment…
  • MDS Virtual Congress 2020

    Treatment characterization and decision-making strategy for first-line pharmacological motor symptomatic therapies in Parkinson’s disease

    M. Javidnia, J. Jones, A. Ertefaie, C. Venuto (Rochester, NY, USA)

    Objective: (1) To characterize motor therapeutic use in the Parkinson’s Progression Markers Initiative (PPMI) early, untreated (de novo) cohort, and (2) to develop an evidence-based…
  • MDS Virtual Congress 2020

    Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson’s disease: A prospective analysis of Thai Apomorphine Registry

    O. Phokaewvarangkul, K. Boonpang, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To evaluate a reduction of LED in PD patients who achieve satisfactory motor control with long-term continuous subcutaneous apomorphine infusion (CSAI) Background: Apomorphine is…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley